Glucocorticoid-sparing in patients suffering from rheumatoid arthritis and treated with tocilizumab: the SPARE-1 study

A. Saraux, S. Rouanet, R.-M. Flipo, J.-C. Poncet, P. Fardellone, P. Hilliquin, I. Idier, A. Cantagrel

Clin Exp Rheumatol 2016

Supplementary tables

Table I. Cortisone dose (with bolus the day of consultation) according to CRP at first infusion [Analysis population (n=307)]

		<=5 mg/l n=110	]5 ; 10] mg/l n=52	]10 ; 15] mg/l n=22	]15 ; 20] mg/l n=19	>20 mg/l n=98	Total n=301
Dose at consultation arrival with bolus (mg/day of equivalent prednisone)	N	110	52	22	19	98	301
	Missing data	0	0	0	0	0	0
	Mean (s.d.)	11.8 (11.2)	16.2 (24.7)	11.1 (5.1)	12.1 (7.2)	19.6 (39.0)	15.1 (25.7)
	Median	10.0	10.0	10.0	10.0	10.0	10.0
	Q1 - Q3	7.5 - 10.0	8.5 - 15.0	8.0 - 10.0	7.0 - 15.0	10.0 - 15.0	7.5 - 15.0
	Min - Max	6.0 - 110.0	6.0 - 157.5	6.0 - 25.0	6.0 - 35.0	6.0 - 332.5	6.0 - 332.5

Table II. Cortisone dose (with bolus the day of consultation) according to CRP at first infusion [Analysis population (n=307)]

Variable	n	Correlation coefficient (Pearson)	*p*-value
CRP at first infusion / Dose at consultation arrival with bolus (mg/day of equivalent prednisone)	301	0.03055	0.5976

Scatter plot and regression line - CRP at first infusion / Dose at consultation arrival with bolus (mg/day of equivalent prednisone)

Table III. EULAR response at 12 months according to TCZ in monotherapy or association at first infusion [Analysis population (n=307)]

		TCZ in monotherapy n=116	TCZ associated with other DMARD n=191	Total n=307
EULAR response at M12 (non assessable response = non response)	n	116	191	307
	Missing data	0	0	0
	Good or moderate	60 (51.7%)	92 (48.2%)	152 (49.5%)
	Non response	56 (48.3%)	99 (51.8%)	155 (50.5%)
	Between group test			0.546 (Chi-2)
EULAR response at M12 (completed patients)	n	64	104	168
	Missing data	52	87	139
	Good or moderate	60 (93.8%)	92 (88.5%)	152 (90.5%)
	Non response	4 (6.3%)	12 (11.5%)	16 (9.5%)
	Between group test			0.257 (Chi-2)
EULAR response at M12 (non assessable response = non response)	n	116	191	307
	Missing data	0	0	0
	Good	43 (37.1%)	72 (37.7%)	115 (37.5%)
	Moderate	17 (14.7%)	20 (10.5%)	37 (12.1%)

		TCZ in monotherapy n=116	TCZ associated with other DMARD n=191	Total n=307
	Non response	56 (48.3%)	99 (51.8%)	155 (50.5%)
	Between group test			0.539 (Chi-2)
EULAR response at M12(completed patients)	N	64	104	168
	Missing data	52	87	139
	Good	43 (67.2%)	72 (69.2%)	115 (68.5%)
	Moderate	17 (26.6%)	20 (19.2%)	37 (22.0%)
	Non response	4 (6.3%)	12 (11.5%)	16 (9.5%)
	Between group test			0.341 (Chi-2)

Table IV. EULAR response at 12 months according to TCZ in monotherapy or association at first infusion [Analysis population - Patients with CRP<=5 mg/l at first infusion (n=110)]

		TCZ in monotherapy n=34	TCZ associated with other DMARD n=76	Total n=110
EULAR response at M12 (non assessable response = non response)	n	34	76	110
	Missing data	0	0	0
	Good or moderate	14 (41.2%)	35 (46.1%)	49 (44.5%)
	Non response	20 (58.8%)	41 (53.9%)	61 (55.5%)
	Between group test			0.634 (Chi-2)
EULAR response at M12 (completed patients)	n	16	42	58
	Missing data	18	34	52
	Good or moderate	14 (87.5%)	35 (83.3%)	49 (84.5%)
	Non response	2 (12.5%)	7 (16.7%)	9 (15.5%)
	Between group test			1.000 (Fisher)
EULAR response at M12 (non assessable response = non response)	n	34	76	110
	Missing data	0	0	0
	Good	10 (29.4%)	28 (36.8%)	38 (34.5%)
	Moderate	4 (11.8%)	7 (9.2%)	11 (10.0%)

		TCZ in monotherapy n=34	TCZ associated with other DMARD n=76	Total n=110
	Non response	20 (58.8%)	41 (53.9%)	61 (55.5%)
	Between group test			0.787 (Fisher)
EULAR response at M12(completed patients)	n	16	42	58
	Missing data	18	34	52
	Good	10 (62.5%)	28 (66.7%)	38 (65.5%)
	Moderate	4 (25.0%)	7 (16.7%)	11 (19.0%)
	Non response	2 (12.5%)	7 (16.7%)	9 (15.5%)
	Between group test			0.829 (Fisher)

Table V. EULAR response at 12 months according to TCZ in monotherapy or association at first infusion [Analysis population - Patients with CRP]5,10] mg/l at first infusion (n=52)]

		TCZ in monotherapy n=16	TCZ associated with other DMARD n=36	Total n=52
EULAR response at M12 (non assessable response = non response)	n	16	36	52
	Missing data	0	0	0
	Good or moderate	9 (56.3%)	17 (47.2%)	26 (50.0%)
	Non response	7 (43.8%)	19 (52.8%)	26 (50.0%)
	Between group test			0.548 (Chi-2)
EULAR response at M12 (completed patients)	n	10	18	28
	Missing data	6	18	24
	Good or moderate	9 (90.0%)	17 (94.4%)	26 (92.9%)
	Non response	1 (10.0%)	1 (5.6%)	2 (7.1%)
	Between group test			1.000 (Fisher)
EULAR response at M12 (non assessable response = non response)	n	16	36	52
	Missing data	0	0	0
	Good	5 (31.3%)	15 (41.7%)	20 (38.5%)
	Moderate	4 (25.0%)	2 (5.6%)	6 (11.5%)

		TCZ in monotherapy n=16	TCZ associated with other DMARD n=36	Total n=52
	Non response	7 (43.8%)	19 (52.8%)	26 (50.0%)
	Between group test			0.155 (Fisher)
EULAR response at M12(completed patients)	n	10	18	28
	Missing data	6	18	24
	Good	5 (50.0%)	15 (83.3%)	20 (71.4%)
	Moderate	4 (40.0%)	2 (11.1%)	6 (21.4%)
	Non response	1 (10.0%)	1 (5.6%)	2 (7.1%)
	Between group test			0.162 (Fisher)

Table VI. EULAR response at 12 months according to TCZ in monotherapy or association at first infusion [Analysis population - Patients with CRPP]10,15] mg/l at first infusion (n=22)]

		TCZ in monotherapy n=9	TCZ associated with other DMARD n=13	Total n=22
EULAR response at M12 (non assessable response = non response)	n	9	13	22
	Missing data	0	0	0
	Good or moderate	5 (55.6%)	9 (69.2%)	14 (63.6%)
	Non response	4 (44.4%)	4 (30.8%)	8 (36.4%)
	Between group test			0.662 (Fisher)
EULAR response at M12 (completed patients)	n	5	10	15
	Missing data	4	3	7
	Good or moderate	5 (100.0%)	9 (90.0%)	14 (93.3%)
	Non response	0	1 (10.0%)	1 (6.7%)
	Between group test			1.000 (Fisher)
EULAR response at M12 (non assessable response = non response)	n	9	13	22
	Missing data	0	0	0
	Good	4 (44.4%)	6 (46.2%)	10 (45.5%)

		TCZ in monotherapy n=9	TCZ associated with other DMARD n=13	Total n=22
	Moderate	1 (11.1%)	3 (23.1%)	4 (18.2%)
	Non response	4 (44.4%)	4 (30.8%)	8 (36.4%)
	Between group test			0.858 (Fisher)
EULAR response at M12(completed patients)	n	5	10	15
	Missing data	4	3	7
	Good	4 (80.0%)	6 (60.0%)	10 (66.7%)
	Moderate	1 (20.0%)	3 (30.0%)	4 (26.7%)
	Non response	0	1 (10.0%)	1 (6.7%)
	Between group test			1.000 (Fisher)

Table VII. EULAR response at 12 months according to TCZ in monotherapy or association at first infusion [Analysis population - Patients with CRP]15,20] mg/l at first infusion (n=19)]

		TCZ in monotherapy n=7	TCZ associated with other DMARD n=12	Total n=19
EULAR response at M12 (non assessable response = non response)	n	7	12	19
	Missing data	0	0	0
	Good or moderate	5 (71.4%)	7 (58.3%)	12 (63.2%)
	Non response	2 (28.6%)	5 (41.7%)	7 (36.8%)
	Between group test			0.656 (Fisher)
EULAR response at M12 (completed patients)	n	6	9	15
	Missing data	1	3	4
	Good or moderate	5 (83.3%)	7 (77.8%)	12 (80.0%)
	Non response	1 (16.7%)	2 (22.2%)	3 (20.0%)
	Between group test			1.000 (Fisher)
EULAR response at M12 (non assessable response = non response)	n	7	12	19
	Missing data	0	0	0
	Good	3 (42.9%)	6 (50.0%)	9 (47.4%)

		TCZ in monotherapy n=7	TCZ associated with other DMARD n=12	Total n=19
	Moderate	2 (28.6%)	1 (8.3%)	3 (15.8%)
	Non response	2 (28.6%)	5 (41.7%)	7 (36.8%)
	Between group test			0.667 (Fisher)
EULAR response at M12(completed patients)	n	6	9	15
	Missing data	1	3	4
	Good	3 (50.0%)	6 (66.7%)	9 (60.0%)
	Moderate	2 (33.3%)	1 (11.1%)	3 (20.0%)
	Non response	1 (16.7%)	2 (22.2%)	3 (20.0%)
	Between group test			0.773 (Fisher)

Table VIII. EULAR response at 12 months according to TCZ in monotherapy or association at first infusion [Analysis population - Patients with CRP>20 mg/l at first infusion (n=98)]

		TCZ in monotherapy n=48	TCZ associated with other DMARD n=50	Total n=98
EULAR response at M12 (non assessable response = non response)	n	48	50	98
	Missing data	0	0	0
	Good or moderate	25 (52.1%)	22 (44.0%)	47 (48.0%)
	Non response	23 (47.9%)	28 (56.0%)	51 (52.0%)
	Between group test			0.423 (Chi-2)
EULAR response at M12 (completed patients)	n	25	23	48
	Missing data	23	27	50
	Good or moderate	25 (100.0%)	22 (95.7%)	47 (97.9%)
	Non response	0	1 (4.3%)	1 (2.1%)
	Between group test			0.479 (Fisher)
EULAR response at M12 (non assessable response = non response)	n	48	50	98
	Missing data	0	0	0
	Good	19 (39.6%)	17 (34.0%)	36 (36.7%)
	Moderate	6 (12.5%)	5 (10.0%)	11 (11.2%)

		TCZ in monotherapy n=48	TCZ associated with other DMARD n=50	Total n=98
	Non response	23 (47.9%)	28 (56.0%)	51 (52.0%)
	Between group test			0.722 (Chi-2)
EULAR response at M12(completed patients)	n	25	23	48
	Missing data	23	27	50
	Good	19 (76.0%)	17 (73.9%)	36 (75.0%)
	Moderate	6 (24.0%)	5 (21.7%)	11 (22.9%)
	Non response	0	1 (4.3%)	1 (2.1%)
	Between group test			0.865 (Fisher)

Table IX. EULAR response at 12 months according to CRP at first infusion [Analysis population - Patients with TCZ in monotherapy (n=116)]

		<=5 mg/l n=34	]5 ; 10] mg/l n=16	]10 ; 15] mg/l n=9	]15 ; 20] mg/l n=7	>20 mg/l n=48	Total n=114
EULAR response at M12 (non assessable response = non response)	n	34	16	9	7	48	114
	Missing data	0	0	0	0	0	0
	Good or moderate	14 (41.2%)	9 (56.3%)	5 (55.6%)	5 (71.4%)	25 (52.1%)	58 (50.9%)
	Non response	20 (58.8%)	7 (43.8%)	4 (44.4%)	2 (28.6%)	23 (47.9%)	56 (49.1%)
EULAR response at M12 (completed patients)	n	16	10	5	6	25	62
	Missing data	18	6	4	1	23	52
	Good or moderate	14 (87.5%)	9 (90.0%)	5 (100.0%)	5 (83.3%)	25 (100.0%)	58 (93.5%)
	Non response	2 (12.5%)	1 (10.0%)	0	1 (16.7%)	0	4 (6.5%)
EULAR response at M12 (non assessable response = non response)	n	34	16	9	7	48	114
	Missing data	0	0	0	0	0	0
	Good	10 (29.4%)	5 (31.3%)	4 (44.4%)	3 (42.9%)	19 (39.6%)	41 (36.0%)
	Moderate	4 (11.8%)	4 (25.0%)	1 (11.1%)	2 (28.6%)	6 (12.5%)	17 (14.9%)
	Non response	20 (58.8%)	7 (43.8%)	4 (44.4%)	2 (28.6%)	23 (47.9%)	56 (49.1%)

		<=5 mg/l n=34	]5 ; 10] mg/l n=16	]10 ; 15] mg/l n=9	]15 ; 20] mg/l n=7	>20 mg/l n=48	Total n=114
EULAR response at M12 (completed patients)	n	16	10	5	6	25	62
	Missing data	18	6	4	1	23	52
	Good	10 (62.5%)	5 (50.0%)	4 (80.0%)	3 (50.0%)	19 (76.0%)	41 (66.1%)
	Moderate	4 (25.0%)	4 (40.0%)	1 (20.0%)	2 (33.3%)	6 (24.0%)	17 (27.4%)
	Non response	2 (12.5%)	1 (10.0%)	0	1 (16.7%)	0	4 (6.5%)

Table X. EULAR response at 12 months according to CRP at first infusion [Analysis population - Patients with TCZ in association (n=191)]

		<=5 mg/l n=76	]5 ; 10] mg/l n=36	]10 ; 15] mg/l n=13	]15 ; 20] mg/l n=12	>20 mg/l n=50	Total n=187
EULAR response at M12 (non assessable response = non response)	n	76	36	13	12	50	187
	Missing data	0	0	0	0	0	0
	Good or moderate	35 (46.1%)	17 (47.2%)	9 (69.2%)	7 (58.3%)	22 (44.0%)	90 (48.1%)
	Non response	41 (53.9%)	19 (52.8%)	4 (30.8%)	5 (41.7%)	28 (56.0%)	97 (51.9%)
EULAR response at M12 (completed patients)	n	42	18	10	9	23	102
	Missing data	34	18	3	3	27	85
	Good or moderate	35 (83.3%)	17 (94.4%)	9 (90.0%)	7 (77.8%)	22 (95.7%)	90 (88.2%)
	Non response	7 (16.7%)	1 (5.6%)	1 (10.0%)	2 (22.2%)	1 (4.3%)	12 (11.8%)
EULAR response at M12 (non assessable response = non response)	n	76	36	13	12	50	187
	Missing data	0	0	0	0	0	0
	Good	28 (36.8%)	15 (41.7%)	6 (46.2%)	6 (50.0%)	17 (34.0%)	72 (38.5%)
	Moderate	7 (9.2%)	2 (5.6%)	3 (23.1%)	1 (8.3%)	5 (10.0%)	18 (9.6%)
	Non response	41 (53.9%)	19 (52.8%)	4 (30.8%)	5 (41.7%)	28 (56.0%)	97 (51.9%)

		<=5 mg/l n=76	]5 ; 10] mg/l n=36	]10 ; 15] mg/l n=13	]15 ; 20] mg/l n=12	>20 mg/l n=50	Total n=187
EULAR response at M12(completed patients)	n	42	18	10	9	23	102
	Missing data	34	18	3	3	27	85
	Good	28 (66.7%)	15 (83.3%)	6 (60.0%)	6 (66.7%)	17 (73.9%)	72 (70.6%)
	Moderate	7 (16.7%)	2 (11.1%)	3 (30.0%)	1 (11.1%)	5 (21.7%)	18 (17.6%)
	Non response	7 (16.7%)	1 (5.6%)	1 (10.0%)	2 (22.2%)	1 (4.3%)	12 (11.8%)

Table XI. Cortisone dose and DMARD intensification at 12 months [Analysis population (n=307)]

		TCZ in monotherapy n=116	TCZ associated with other DMARD n=191	Total n=307
Patient treated by 5 mg/day of equivalent prednisone or less without DMARD intensification after 12 months of treatment (non assessable response =	n	116	191	307
	Missing data	0	0	0
	No	74 (63.8%)	109 (57.1%)	183 (59.6%)
	Yes	42 (36.2%)	82 (42.9%)	124 (40.4%)
	Between group test			0.244 (Chi-2)
Patient treated by 5 mg/day of equivalent prednisone or less without DMARD intensification after 12 months of treatment (completed patients)	n	69	115	184
	Missing data	47	76	123
	No	27 (39.1%)	33 (28.7%)	60 (32.6%)
	Yes	42 (60.9%)	82 (71.3%)	124 (67.4%)
	Between group test			0.144 (Chi-2)